HEMATOLOGY / RESEARCH LETTER
 
TOPICS
REFERENCES (15)
1.
Kroeze E, Loeffen J, Poort VM, Meijerink JP. T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? Blood Adv 2020; 4: 3466-73.
 
2.
Swoboda R, Labopin M, Giebel S, et al. Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. BMC Cancer 2025; 25: 787.
 
3.
Saygin C, Cannova J, Stock W, Muffly L. Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica 2022; 107: 2783-93.
 
4.
Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, et al. Status of minimal residual disease determines outcome of autologous hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia. Bone Marrow Transplant 2010; 45: 1095-101.
 
5.
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36: 1720-48.
 
6.
Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging 2017; 44 (Suppl 1): 97-110.
 
7.
Giebel S, Kruzel T, Czerw T, et al. Intermediate-dose cytarabine plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers. Bone Marrow Transplant 2013; 48: 915-21.
 
8.
Chrzanowska KH, Gregorek H, Dembowska-Baginska B, Kalina MA, Digweed M. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis 2012; 7: 13.
 
9.
Giebel S, Labopin M, Socié G, et al. Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant 2023; 58: 506-13.
 
10.
Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood 2015; 126: 833-41.
 
11.
Yu H, Mi L, Qi F, et al. Survival and prognostic analysis of T-cell lymphoblastic lymphoma patients treated with dose-adjusted BFM-90 regimen. Aging 2022; 14: 3203-13.
 
12.
Parovichnikova E, Troitskaya V, Sokolov A, et al. Can less intensive chemotherapy and autotransplant cure adult T-cell acute lymphoblastic leukemia? Acta Haematol 2020; 143: 131-9.
 
13.
Law MF, Chan HN, Kong SY, et al. Clinical outcomes of patients with acute lymphoblastic leukemia receiving the hyper-CVAD regimen and assessment of the risk of hepatitis flares due to hepatitis B virus reactivation after chemotherapy. Arch Med Sci 2022; 18: 121-8.
 
14.
Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG2993 study. Blood 2007; 109: 944-50.
 
15.
Ellin F, Jerkeman M, Hagberg H, Relander T. Treatment outcomes in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry. Acta Oncol 2014; 53: 927-34.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top